UB Paderborn / Katalog / Suche / in CDI

1 – 16 von 16

Sortiert nach

A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam

International journal of infectious diseases, 2019-12, Vol.89, p.55-61

2019

Volltextzugriff (PDF)

Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model

Antimicrobial agents and chemotherapy, 2018-05, Vol.62 (5)

2018

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections

CPT: pharmacometrics and systems pharmacology, 2019-10, Vol.8 (10), p.748-758

2019

Volltextzugriff (PDF)

Modeling heterogeneous bacterial populations exposed to antibiotics: The logistic-dynamics case

AIChE journal, 2015-08, Vol.61 (8), p.2385-2393

2015

Volltextzugriff (PDF)

Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors

Antimicrobial Agents and Chemotherapy, 2012-05, Vol.56 (5), p.2237-2240

2012

Volltextzugriff (PDF)

Discovery of Efficacious Pseudomonas aeruginosa-Targeted Siderophore-Conjugated Monocarbams by Application of a Semi-mechanistic Pharmacokinetic/Pharmacodynamic Model

Journal of medicinal chemistry, 2015-03, Vol.58 (5), p.2195-2205

2015

Volltextzugriff (PDF)

A Population Pharmacokinetic (PopPK) Model to Characterize Efanesoctocog Alfa (BIVV001) Factor VIII (FVIII) Activity Levels in Patients with Severe Hemophilia A

Blood, 2022-11, Vol.140 (Supplement 1), p.8449-8450

2022

Volltextzugriff (PDF)

Mathematical Modeling To Characterize the Inoculum Effect

Antimicrobial Agents and Chemotherapy, 2010-11, Vol.54 (11), p.4739-4743

2010

Volltextzugriff (PDF)

Development of a Quantitative Systems Pharmacology Model to Explore Hemostatic Equivalency of Antithrombin Lowering

Blood, 2022-11, Vol.140 (Supplement 1), p.5606-5607

2022

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants

Antimicrobial agents and chemotherapy, 2018-09, Vol.62 (9)

2018

Volltextzugriff (PDF)

Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin

British journal of clinical pharmacology, 2020-05, Vol.86 (5), p.944-957

2020

Volltextzugriff (PDF)

Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment

European journal of clinical pharmacology, 2019-05, Vol.75 (5), p.665-675

2019

Volltextzugriff (PDF)

Erratum for Rhee et al., "Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants"

Antimicrobial agents and chemotherapy, 2018-12, Vol.62 (12)

2018

Volltextzugriff (PDF)

Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants

Clinical pharmacology in drug development, 2020-05, Vol.9 (4), p.466-475

2020

Volltextzugriff (PDF)

Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for ?-Lactamase Inhibitors

Antimicrobial agents and chemotherapy, 2012-05, Vol.56 (5), p.2237-2240

2012

Volltextzugriff (PDF)

Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design

Journal of antimicrobial chemotherapy, 2011-05, Vol.66 (5), p.1079-1086

2011

Volltextzugriff (PDF)

1 – 16 von 16

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(16)

Sprache

Englisch
(16)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam

Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections

Modeling heterogeneous bacterial populations exposed to antibiotics: The logistic-dynamics case

Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors

Discovery of Efficacious Pseudomonas aeruginosa-Targeted Siderophore-Conjugated Monocarbams by Application of a Semi-mechanistic Pharmacokinetic/Pharmacodynamic Model

A Population Pharmacokinetic (PopPK) Model to Characterize Efanesoctocog Alfa (BIVV001) Factor VIII (FVIII) Activity Levels in Patients with Severe Hemophilia A

Mathematical Modeling To Characterize the Inoculum Effect

Development of a Quantitative Systems Pharmacology Model to Explore Hemostatic Equivalency of Antithrombin Lowering

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants

Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin

Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment

Erratum for Rhee et al., "Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants"

Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants

Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for ?-Lactamase Inhibitors

Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design

Suchergebnisse filtern